Development of Separation Methods for GLP-1 Synthetic Peptides Utilizing a Systematic Protocol and MaxPeak™ High Performance Surface Technology

Význam tématu

Glucagon-like peptide-1 (GLP-1) agonists represent a rapidly expanding class of peptide therapeutics for type II diabetes and obesity management. Ensuring the purity and identity of these synthetic peptides and their process- or degradation-related impurities is vital for product safety, regulatory compliance and clinical efficacy.

Cíle a přehled studie

• Develop a single, reproducible HPLC-UV/MS method to separate a comprehensive panel of marketed GLP-1 peptides (e.g. semaglutide, liraglutide, exenatide).
• Demonstrate impurity profiling, focusing on glucagon desamido variants.
• Evaluate the impact of MaxPeak™ High Performance Surface (HPS) Technology versus traditional stainless-steel systems.

Použitá metodika a instrumentace

The method was built on a systematic column screening protocol using Waters™ MaxPeak Premier Reversed-phase Column Screening Kit. Key instrumentation and consumables:

• HPLC system controlled by Empower™ 3.7.0
• ACQUITY™ QDa™ mass detector for peptide mass confirmation
• Columns: XSelect Premier Peptide CSH C18, XBridge Peptide BEH C18 and alternatives from the screening kit
• Mobile phases: 0.1% formic acid or 0.1% trifluoroacetic acid in water/acetonitrile gradients
• MaxPeak HPS Technology for reduced peptide–metal interactions

Hlavní výsledky a diskuse

• Screening identified XSelect Premier Peptide CSH C18 with formic acid mobile phases as optimal for speed, resolution and peak intensity.
• Focused gradient improved baseline separation of glucagon desamido impurities (four variants) with confirmed UV peak purity and characteristic mass spectra.
• MaxPeak HPS vs. stainless steel:

• Up to 28% increase in peak area
• Up to 51% increase in peak height
• Up to 36% reduction in tailing

Přínosy a praktické využití metody

The unified HPLC-UV/MS approach enables simultaneous assay of multiple GLP-1 analogs and their impurities, reducing method development time. Coupled with peak purity assessment and mass detection, it provides robust quality control for pharmaceutical development and regulatory submissions.

Budoucí trendy a možnosti využití

Advances may include integration with high-resolution MS for deeper impurity characterization, automation of column screening for peptide libraries, and application of HPS technology across broader peptide classes to further improve recovery and reproducibility.

Závěr

A systematic protocol combined with MaxPeak HPS Technology yields a versatile, high-performance HPLC-UV/MS method for comprehensive analysis of GLP-1 synthetic peptides and related impurities. This approach streamlines method development and enhances chromatographic performance compared to traditional systems.

Reference

1. Holz G, Chepurny O. Curr Med Chem. 2003;10(22):2471–83.
2. Wojtara MS, et al. Adv Med. 2023;2023:9946924.
3. United States Pharmacopeia. Exenatide Injection USP Monograph. 2019.
4. United States Pharmacopeia. Glucagon USP Monograph. 2022.
5. Kuna AK, Ganapathi S, Radha G. Int J Res Pharm Sci. 2019;10(2):865–73.
6. Pedaprolu JN, et al. Eurasian J Anal Chem. 2016;12(2):31–44.
7. FDA. Synthetic Peptide Guidance and PSGs. 2020.
8. Birdsall R, et al. Waters Application Note. 2021.
9. Bigos P, et al. Waters Tech Brief. 2021.
10. Waters. MaxPeak Premier Screening Kit. 2021.
11. Bao Z, et al. Sci Pharm. 2022;90(2):32.